Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 301–400 of 1,008
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118588 · Cited by 231
“One of the major mechanisms of resistance to imatinib is via the occurrence of point mutations in the kinase domain or amplification of the BCR-ABL signal.(45,46) BCR-ABL kinase point mutations may be present at the time of diagnosis conferring primary resistance or may be acquired during therapy with imatinib.”
BackgroundAmplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A., Lifshits, E., Brown, A., Lee, C., Christensen, J. G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.526 · Cited by 228
“Secondary mutations at the gatekeeper residue are among the most common mechanisms of acquired resistance to kinase inhibitors (Gorre et al., 2001; Shah et al., 2002; Cools et al., 2003; Tamborini et al., 2004; Bradeen et al., 2006).”
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Pui, C.-H., & Jeha, S. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2240 · Cited by 236
Evolution of Resistance During Clonal Expansion
Iwasa, Y., Nowak, M. A., & Michor, F. (2006) · Genetics · doi:10.1534/genetics.105.049791 · Cited by 233
“For example, treatment of chronic myeloid leukemia with the chemotherapeutic agent imatinib fails due to resistance acquired through a single point mutation in the kinase domain of BCR-ABL, the oncogene driving this disease (Gorre et al. 2001).”
BackgroundMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 231
Du, J., Bernasconi, P., Clauser, K. R., Mani, D. R., Finn, S. P., Beroukhim, R., Burns, M., Julian, B., Peng, X. P., Hieronymus, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1513 · Cited by 232
“This threonine is essential for ABL1 kinase sensitivity to imatinib (Gleevec) and dasatinib, and a specific mutation (T315I) has been observed in individuals with CML who develop imatinib or dasatinib resistanc”
BackgroundPtasznik, A., Nakata, Y., Kalota, A., Emerson, S. G., & Gewirtz, A. M. (2004) · Nature Medicine · doi:10.1038/nm1127 · Cited by 228
Barok, M., Isola, J., Pályi-Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0766 · Cited by 231
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
“Despite the paramount clinical success of gleevec, resistance also develops by acquisition of mutations in the binding site of gleevec (86).”
BackgroundShah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., Nicaise, C., & Sawyers, C. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.001 · Cited by 230
“Peripheral blood mononuclear cell (PBMC) isolation, preparation of whole-cell extracts, and CRKL immunoblotting were performed as described previously (Gorre et al., 2001).”
BackgroundMethodInfluentialSelf-citationChromosomal Abnormalities in Cancer
Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A. S., Ma, Y., Longley, B. J., & Metcalfe, D. D. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00112-7 · Cited by 224
“developed resistance to STI571 [24].”
Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 226
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
“Sawyers’ group reported that BCR-ABL1 could escape from inhibition [73].”
BackgroundInfluentialTyrosine kinases as targets in cancer therapy – successes and failures
Traxler, P. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.215 · Cited by 226
Therapy for metastatic melanoma: the past, present, and future
Finn, L., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 218
Khorashad, J. S., Kelley, T. W., Szankasi, P., Mason, C. C., Soverini, S., Adrian, L. T., Eide, C. A., Zabriskie, M. S., Lange, T., Estrada, J. C., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431379 · Cited by 222
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
Osman, A. E. G., & Deininger, M. W. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100825 · Cited by 203
Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., & Bhalla, K. (2003) · Blood · doi:10.1182/blood-2002-08-2675 · Cited by 222
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 209
“The expression of the ERD7 is associated with a Basal subtype of breast cancers expressing ERa mRNA (Groenendijk et al., 2013).”
BackgroundQi, J., McTigue, M. A., Rogers, A., Lifshits, E., Christensen, J. G., Jänne, P. A., & Engelman, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1623 · Cited by 216
Steinberg, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.005 · Cited by 219
Gastrointestinal stromal tumor: 5 years later
van der Zwan, S. M., & DeMatteo, R. P. (2005) · Cancer · doi:10.1002/cncr.21419 · Cited by 218
“This is consistent with the predominant mechanism of imatinib resistance in CML, which has been shown to be due to second-site mutation in BCR-ABL.(45,46) It is interesting to note that many of the secondary mutations in GIST occur at novel sites of mutation in exons 13, 14, and 17.”
BackgroundBiological and clinical implications of EGFR mutations in lung cancer
Mitsudomi, T., Kosaka, T., & Yatabe, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0583-4 · Cited by 216
“In the case of chronic myeloid leukemia (CML), secondary mutations in the kinase domain of the ABL1 gene are considered to be one of the mechanisms of acquired drug resistance to imatinib, a tyrosine kinase inhibitor specific for BCR–ABL1, KIT, and PDGFA.(39,40) The structural similarity between ABL1 and EGFR tyrosine…”
BackgroundMechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias
Shah, N. P., & Sawyers, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206942 · Cited by 216
“Significantly, BCR-ABL enzymatic activity is reinstated in the majority of patients at the time of relapse, suggesting that BCR-ABL activity remains essential for the leukemic clone (Gorre et al., 2001).”
BackgroundSelf-citationMao, X., Rong Yu, C., Hua Li, W., & Xin Li, W. (2008) · Cell Research · doi:10.1038/cr.2008.86 · Cited by 218
Borst, P. (2012) · Open Biology · doi:10.1098/rsob.120066 · Cited by 212
“In the case of kinase inhibitors, such as imatinib (Gleevec), a major mechanism of resistance is the presence of a small sub-population of leukaemic cells in which the ABL kinase, the target of imatinib, contains an amino acid substitution that prevents inhibition by imatinib [30].”
Levis, M., Pham, R., Smith, B. D., & Small, D. (2004) · Blood · doi:10.1182/blood-2004-01-0388 · Cited by 216
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., Obeid, L. M., & Ogretmen, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610157200 · Cited by 211
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A., Wang, Y., Cai, D., von Bubnoff, N., Paschka, P., Müller-Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., & Neubauer, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403898 · Cited by 213
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.003 · Cited by 208
“However, mutation of the gatekeeper residue, threonine 315, to isoleucine (T315I) causes virtually absolute resistance to all four TKIs, in part through steric interference with drug binding (Gorre et al., 2001).”
BackgroundInfluentialA murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
Dash, A. B., Williams, I. R., Kutok, J. L., Tomasson, M. H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R. A., Borrow, J., Housman, D., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102583199 · Cited by 209
Antonescu, C. R., Viale, A., Sarran, L., Tschernyavsky, S. J., Gonen, M., Segal, N. H., Maki, R. G., Socci, N. D., DeMatteo, R. P., & Besmer, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0715 · Cited by 210
“After the initial success, STI571 resistance is now being encountered not only in chronic myelogenous leukemia (32, 33), but also in patients with GIST who had an initial therapeutic response (34).”
BackgroundPiloto, O., Wright, M., Brown, P., Kim, K.-T., Levis, M., & Small, D. (2007) · Blood · doi:10.1182/blood-2006-05-023804 · Cited by 204
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R., Aggarwal, B., Shishodin, S., Albitar, M., Hayes, K., Kantarjian, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1484 · Cited by 214
Tauchi, T., Shin-ya, K., Sashida, G., Sumi, M., Nakajima, A., Shimamoto, T., Ohyashiki, J. H., & Ohyashiki, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206833 · Cited by 206
“Imatinib is specifically active both in vitro and in vivo against a variety of BCR-ABL transformed cells (Druker et al., 1996; 2001; Gorre et al., 2001; Nakajima et al., 2001).”
BackgroundBranford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832253 · Cited by 210
Cancer BiomarkersAn Invitation to the Table
Dalton, W. S., & Friend, S. H. (2006) · Science · doi:10.1126/science.1125948 · Cited by 202
Brown, P., Levis, M., Shurtleff, S., Campana, D., Downing, J., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-06-2498 · Cited by 212
How I treat chronic myeloid leukemia in the imatinib era
Goldman, J. M. (2007) · Blood · doi:10.1182/blood-2007-04-038943 · Cited by 212
Godin-Heymann, N., Ulkus, L., Brannigan, B. W., McDermott, U., Lamb, J., Maheswaran, S., Settleman, J., & Haber, D. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2387 · Cited by 203
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0065 · Cited by 208
Chu, S., Xu, H., Shah, N. P., Snyder, D. S., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2005) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 209
Self-citationPatel, A. B., O’Hare, T., & Deininger, M. W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.007 · Cited by 204
“One indication that these relationships are complex is the seemingly paradoxic observation that primary CD34(1) CML cells engineered to express high levels of BCR-ABL1 have been reported to exhibit increased sensitivity to imatinib in vitro.(19,28,36,37)”
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B., & Scheinberg, D. A. (2004) · Blood · doi:10.1182/blood-2003-03-0954 · Cited by 208
Brendel, C., Scharenberg, C., Dohse, M., Robey, R. W., Bates, S. E., Shukla, S., Ambudkar, S. V., Wang, Y., Wennemuth, G., Burchert, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404638 · Cited by 200
Bixby, D., & Talpaz, M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.461 · Cited by 204
Nicolini, F. E., Corm, S., Lê, Q.-H., Sorel, N., Hayette, S., Bories, D., Leguay, T., Roy, L., Giraudier, S., Tulliez, M., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404236 · Cited by 207
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Tovar, V., Cornella, H., Moeini, A., Vidal, S., Hoshida, Y., Sia, D., Peix, J., Cabellos, L., Alsinet, C., Torrecilla, S., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-309501 · Cited by 206
Gilliland, D. G., & Griffin, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00003 · Cited by 202
Mastocytosis: current concepts in diagnosis and treatment
L., E., C., A., M., C., A., O., & D., M. (2002) · Annals of Hematology · doi:10.1007/s00277-002-0575-z · Cited by 201
Rosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 225
Rothe, K., Lin, H., Lin, K. B. L., Leung, A., Wang, H. M., Malekesmaeili, M., Brinkman, R. R., Forrest, D. L., Gorski, S. M., & Jiang, X. (2014) · Blood · doi:10.1182/blood-2013-07-516807 · Cited by 199
Griswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 200
“Mutations in the kinase domain (KD) of Bcr-Abl that impair imatinib binding have been identified as the major mechanism of acquired resistance (1, 3, 13, 15, 34, 37).”
BackgroundSTI571: A Paradigm of New Agents for Cancer Therapeutics
Mauro, M. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.325 · Cited by 202
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., & Briesewitz, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932698100 · Cited by 202
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Measuring and interpreting the selectivity of protein kinase inhibitors
Smyth, L. A., & Collins, I. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0023-9 · Cited by 197
“One of these mutations is T315I, which is a gatekeeper mutation preventing inhibitor access to the hydrophobic pocket and removing one of the crucial hydrogen bond donors used for imatinib binding [62, 143].”
Warsch, W., Kollmann, K., Eckelhart, E., Fajmann, S., Cerny-Reiterer, S., Hölbl, A., Gleixner, K. V., Dworzak, M., Mayerhofer, M., Hoermann, G., et al. (2011) · Blood · doi:10.1182/blood-2009-10-248211 · Cited by 194
Tyrosine kinase receptors as attractive targets of cancer therapy
Bennasroune, A., Gardin, A., Aunis, D., Crémel, G., & Hubert, P. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.08.004 · Cited by 197
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Schiffer, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071828 · Cited by 199
Branford, S., Melo, J. V., & Hughes, T. P. (2009) · Blood · doi:10.1182/blood-2009-08-215939 · Cited by 200
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer
Coward, J., & Harding, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00123 · Cited by 192
“Does the cell number 10 (9) still really fit one gram of tumor tissue.”
BackgroundLee, S., Kim, Y.-J., Min, C.-K., Kim, H.-J., Eom, K.-S., Kim, D.-W., Lee, J.-W., Min, W.-S., & Kim, C.-C. (2005) · Blood · doi:10.1182/blood-2004-09-3785 · Cited by 196
“Median age, y (range) 36 (18-55) 35 (15-48) .”
Tumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 194
Ren, X., Pan, X., Zhang, Z., Wang, D., Lu, X., Li, Y., Wen, D., Long, H., Luo, J., Feng, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301581y · Cited by 181
Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., Xu, C., Wang, Y., Adelmant, G. O., Capelletti, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1671 · Cited by 191
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
“Another potential mechanism of imatinib resistance that might be overcome by dasatinib is BCR-ABL amplification.(27,28) However, a considerable proportion of the patients in this study demonstrated clinical resistance without evidence of Table 3.”
BackgroundKamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 191
“The current frontline therapy for CML is imatinib (GleevecTM), an orally available inhibitor of BCR-ABL [3].”
InfluentialGetting to the stem of chronic myeloid leukaemia
Savona, M., & Talpaz, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2368 · Cited by 192
“As imatinib mesylate reverses autophosphorylation of BCR–ABL and thereby inhibits dependent intracellular signal transduction, measurement of downstream signalling events, particularly phosphorylation of the adaptor molecule CRKL , has been used as a surrogate for establishing the level of BCR–ABL tyrosine kinase bloc…”
MethodMechanisms of drug resistance in kinases
Barouch-Bentov, R., & Sauer, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.546344 · Cited by 181
“They usually harbor missense mutations, although small deletions and insertions can also occur [3,13,16,22,26,55,68].”
BackgroundInfluentialWorkman, P., Aboagye, E. O., Chung, Y.-L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., & Zweit, J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 188
Shoaib Ahmad Shah, S., Rivera, G., & Ashfaq, M. (2013) · Mini Reviews in Medicinal Chemistry · doi:10.2174/138955713804484749 · Cited by 184
FOJO, T. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.02.002 · Cited by 191
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
Misaghian, N., Ligresti, G., Steelman, L. S., Bertrand, F. E., Bäsecke, J., Libra, M., Nicoletti, F., Stivala, F., Milella, M., Tafuri, A., et al. (2009) · Leukemia · doi:10.1038/leu.2008.246 · Cited by 187
Chen, S.-J., Zhou, G.-B., Zhang, X.-W., Mao, J.-H., de Thé, H., & Chen, Z. (2011) · Blood · doi:10.1182/blood-2010-11-283598 · Cited by 183
“However, IM(135;136) and Dasatinib(136;137) do not deplete LICs, while a proportion of patients develops IM-resistance,(136;138-140) and patients with advanced stage disease respond initially but then relapse.(136;141) Moreover, cardiotoxicity of IM was also reported.”
BackgroundGarrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 178
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Nardi, V., Azam, M., & Daley, G. Q. (2004) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00006 · Cited by 191
mTOR pathway in colorectal cancer: an update
Francipane, M. G., & Lagasse, E. (2014) · Oncotarget · doi:10.18632/oncotarget.1548 · Cited by 182
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
Michael, M., & Doherty, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.120 · Cited by 177
Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence
Takeishi, S., Matsumoto, A., Onoyama, I., Naka, K., Hirao, A., & Nakayama, K. I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.026 · Cited by 178
“Several mechanisms underlying resistance to imatinib have been proposed, including quiescence, BCR-ABL mutations such as T315I, and the lack of addiction to BCR-ABL in LICs (Corbin et al., 2011; Gorre et al., 2001; Holtz et al., 2007).”
BackgroundKim, D. H. (., Sriharsha, L., Xu, W., Kamel-Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0145 · Cited by 186
“*Additional cytogenetic findings were detected: -Y (n = 5); double Ph chromosome (n = 5); t(7;8) (n = 2); t(9;22;22) (n = 2); t(2;9;22) (n = 2); t(9;22;17) (n = 1); t(1;22;18) with inv (5) (n = 1); t(7;8) with +8 and +der(22) (n = 1); t(8;17) (n = 1); t(8;16) (n = 1); inv (9q) (n = 1); -18q (n = 1); t(12;16) (n = 1);…”
BackgroundWang, T.-L., Diaz, L. A., Romans, K., Bardelli, A., Saha, S., Galizia, G., Choti, M., Donehower, R., Parmigiani, G., Shih, I.-M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308716101 · Cited by 183
Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Prediction of Resistance to Small Molecule FLT3 Inhibitors
Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J. J., Griffin, J. D., Marynen, P., & Gilliland, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2148 · Cited by 178
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179
“Similar observations with BCR-ABL-driven tumors were noted in imatinib-resistant cell lines (26, 27) and relapsed patients (28).”
ResultPawlik, T. M. (2006) · Archives of Surgery · doi:10.1001/archsurg.141.6.537 · Cited by 182
“Although initial reports noted a durable response for imatinib mesylate,(47) it has subsequently become evident that with extended follow-up, tumor recurrence or progression can occur despite an initial response to imatinib mesylate therapy.(46,48,49) For this reason, surgical resection should remain the mainstay of t…”
BackgroundKhorashad, J. S., de Lavallade, H., Apperley, J. F., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9953 · Cited by 183
“This resistance has been ascribed to several possible mechanisms (reviewed by Apperley(6)) but perhaps the best understood and certainly the most widely documented in clinical practice is the expansion of a Ph-positive clone bearing a mutation in the BCR-ABL kinase domain (KD).(7,8) To date, more than 50 different KD…”
BackgroundZhao, F., Mancuso, A., Bui, T. V., Tong, X., Gruber, J. J., Swider, C. R., Sanchez, P. V., Lum, J. J., Sayed, N., Melo, J. V., et al. (2010) · Oncogene · doi:10.1038/onc.2010.67 · Cited by 179
“Oxythiamine improves the efficacy of imatinib in primary CML cells isolated from patients in the accelerated/ blastic phase of the disease BCR-ABL amplification has been shown in patients with CML when the disease progresses into the accelerated/blastic phase and BCR-ABL-expressing cells become resistant to imatinib (…”
InfluentialSawai, A., Chandarlapaty, S., Greulich, H., Gonen, M., Ye, Q., Arteaga, C. L., Sellers, W., Rosen, N., & Solit, D. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1570 · Cited by 179
“This second-site mutation in EGFR, which is analogous to the T315I ‘‘gatekeeper’’ mutation that confers resistance of bcr-abl to imatinib (9), is predicted to block binding of erlotinib and gefitinib to the EGFR ATP-binding domain.”
Genetic and Biological Subgroups of Low-Stage Follicular Thyroid Cancer
French, C. A., Alexander, E. K., Cibas, E. S., Nose, V., Laguette, J., Faquin, W., Garber, J., Moore, F., Fletcher, J. A., Larsen, P. R., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63902-8 · Cited by 175
“Such rearrangements in leukemias play a primary role in establishment and maintenance of malignancy and in induction of clinical remission by drugs that target activities of the encoded fusion oncoproteins.(5,7,8) Gene rearrangements are now used commonly in the molecular diagnosis of cancer.”
BackgroundIns and Outs of Kinase DFG Motifs
Treiber, D. K., & Shah, N. P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.001 · Cited by 173
A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity
Levinson, N. M., & Boxer, S. G. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1404 · Cited by 171
Common pitfalls in preclinical cancer target validation
Kaelin, W. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.32 · Cited by 175
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 172
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.